Fig. 8

Cyp4a10 and Cyp4a11/12 are expressed by mouse and human cholangiocytes and hepatocytes, respectively. A Measurement of immunoreactivity for Cyp4a10 in liver sections (co-stained with CK19 or HNF4α) from selected mouse groups (n ≥ 3/group) by immunofluorescence. Orig. magn. 20X, scale bar: 100 μM. There was enhanced biliary immunoreactivity of Cyp4a10 in EtOH-fed WT mice compared to CD-fed WT mice. The Cyp4a10 positive area % refers to both cholangiocytes and hepatocytes immunoreactive for Cyp4a10. *p < 0.05 vs. CD-fed WT mice; ^#p < 0.05 vs. EtOH-fed WT mice. B In EtOH-fed WT mice, there was enhanced expression of Cyp4a10 (in isolated hepatocytes and cholangiocytes) compared to CD-fed WT mice, which was reduced in EtOH-fed Sct^−/− mice. Data are mean ± SEM of 3 experiments from selected mice groups (n ≥ 3/group). *p < 0.05 vs. CD-fed WT mice; ^#p < 0.05 vs. EtOH-fed WT mice. C Measurement of immunoreactivity for Cyp4a11/22 in liver sections (co-stained with CK19 or HNF4α) from human healthy controls (n = 2) and patients with alcoholic cirrhosis (n = 2) by immunofluorescence; immunoreactivity of Cyp4a11/22 was measured in paraffin-embedded liver sections from human control (n = 8) and patients with alcoholic cirrhosis (n = 8) by immunohistochemistry. Orig. magn. 20X, scale bar: 100 μm. White arrows indicate Cyp4a10- and Cyp4a11/22- positive cells. Black arrows show Cyp4a11/22-positive cells